The role of microenvironment and immunity in drug response in leukemia

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1863, Issue 3, 2016, Pages 414-426

  Bakker, Emyr ^a   Qattan, Malak ^b   Mutti, Luciano ^a   Demonacos, Constantinos ^c   Krstic Demonacos, Marija ^a  

^a UNIVERSITY OF SALFORD   (United Kingdom)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cancer; Immune surveillance; Inflammation; Leukemia; Microenvironment; Novel therapeutics

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN; ANTINEOPLASTIC AGENT;

CANCER RESISTANCE; CELL INTERACTION; HUMAN; IMMUNITY; IMMUNOSURVEILLANCE; INFLAMMATION; LEUKEMIA; LEUKEMIA CELL; MEMBRANE MICROPARTICLE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; BIOLOGICAL MODEL; BONE MARROW; BONE MARROW CELL; CANCER STEM CELL; CLASSIFICATION; DRUG EFFECTS; DRUG RESISTANCE; IMMUNOLOGY; PATHOLOGY;

ANTINEOPLASTIC AGENTS; BONE MARROW; BONE MARROW CELLS; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNITY; LEUKEMIA; MODELS, IMMUNOLOGICAL; NEOPLASTIC STEM CELLS; TUMOR MICROENVIRONMENT;

EID: 84955184912     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2015.08.003     Document Type: Review

References (190)

1. Burger J.A. Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. ASH Education Program Book 2011, 2011(1):96-103.
2. Greim H., et al. The bone marrow niche, stem cells, and leukemia: impact of drugs, chemicals, and the environment. Ann. N. Y. Acad. Sci. 2014, 1310:7-31.
3. Lane S.W., Scadden D.T., Gilliland D.G. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 2009, 114(6):1150-1157.
4. Wang L.D., Wagers A.J. Dynamic niches in the origination and differentiation of haematopoietic stem cells. Nat. Rev. Mol. Cell Biol. 2011, 12(10):643-655.
5. Dingli D., Pacheco J.M. Modeling the architecture and dynamics of hematopoiesis. Wiley Interdiscip. Rev. Syst. Biol. Med. 2010, 2(2):235-244.
6. Lapidot T., Dar A., Kollet O. How do stem cells find their way home?. Blood 2005, 106(6):1901-1910.
7. Singh V., Erb U., Zöller M. Cooperativity of CD44 and CD49d in leukemia cell homing, migration, and survival offers a means for therapeutic attack. J. Immunol. 2013, 191(10):5304-5316.
8. Witz I. The tumor microenvironment: the making of a paradigm. Cancer Microenviron. 2009, 2(1):9-17.
9. Nwajei F., Konopleva M. The bone marrow microenvironment as niche retreats for hematopoietic and leukemic stem cells. Adv. Hematol. 2013, 2013:8.
10. Morrison S.J., Scadden D.T. The bone marrow niche for haematopoietic stem cells. Nature 2014, 505(7483):327-334.
11. Kiel M.J., Morrison S.J. Uncertainty in the niches that maintain haematopoietic stem cells. Nat. Rev. Immunol. 2008, 8(4):290-301.
12. Yin T., Li L. The stem cell niches in bone. J. Clin. Invest. 2006, 116(5):1195-1201.
13. Ajani J.A., et al. Cancer stem cells: the promise and the potential. Semin. Oncol. 2015, 42:S3-S17.
14. Riether C., Schurch C.M., Ochsenbein A.F. Regulation of hematopoietic and leukemic stem cells by the immune system. Cell Death Differ. 2015, 22(2):187-198.
15. Civini S., et al. Leukemia cells induce changes in human bone marrow stromal cells. J. Transl. Med. 2013, 11:298-298.
16. Tabe Y., Konopleva M. Advances in understanding the leukaemia microenvironment. Br. J. Haematol. 2014, 164(6):767-778.
17. + in B-lineage childhood acute lymphoblastic leukemia. Haematologica 2010, 95(4):679-683.
18. Konopleva M.Y., Jordan C.T. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J. Clin. Oncol. 2011, 29(5):591-599.
19. Saito Y., et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat. Biotechnol. 2010, 28(3):275-280.
20. + chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL. PLoS ONE 2015, 10(4).
21. Sinclair A., Latif A.L., Holyoake T.L. Targeting survival pathways in chronic myeloid leukaemia stem cells. Br. J. Pharmacol. 2013, 169(8):1693-1707.
22. Konopleva M., et al. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 2002, 16(9):1713-1724.
23. Meads M.B., Hazlehurst L.A., Dalton W.S. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin. Cancer Res. 2008, 14(9):2519-2526.
24. Chien W.W., et al. Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines. Sci. Rep. 2015, 5:8068.
25. Shigemi H., et al. Novel leukemic cell lines resistant to clofarabine by mechanisms of decreased active metabolite and increased antiapoptosis. Cancer Sci. 2013, 104(6):732-739.
26. Karp J.E. MDR modulation in acute myelogenous leukemia: is it dead?. Leukemia 2001, 15(4):666-667.
27. Baran Y., et al. Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance. Hematology 2007, 12(6):511-517.
28. Fotoohi A.K., Albertioni F. Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells. Leuk. Lymphoma 2008, 49(3):410-426.
29. Ong V., et al. A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts. J. Pharmacol. Exp. Ther. 2008, 324(2):434-442.
30. Bachmann P.S., et al. Dexamethasone resistance in B-cell precursor childhood acute lymphoblastic leukemia occurs downstream of ligand-induced nuclear translocation of the glucocorticoid receptor. Blood 2005, 105(6):2519-2526.
31. Miller A.L., et al. Epigenetic alteration by DNA-demethylating treatment restores apoptotic response to glucocorticoids in dexamethasone-resistant human malignant lymphoid cells. Cancer Cell Int. 2014, 14:35.
32. Chen D.W., et al. Erg and AP-1 as determinants of glucocorticoid response in acute lymphoblastic leukemia. Oncogene 2013, 32(25):3039-3048.
33. Schmidt S., et al. Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ. 2004, 11:S45-S55.
34. Miyashita T., Reed J.C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993, 81(1):151-157.
35. Galmarini C.M., et al. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br. J. Haematol. 2002, 117(4):860-868.
36. Ma P., et al. Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia. J. Biomed. Nanotechnol. 2009, 5(2):151-161.
37. Hermanson D.L., et al. Overexpression of Mcl-1 confers multidrug resistance, whereas topoisomerase IIbeta downregulation introduces mitoxantrone-specific drug resistance in acute myeloid leukemia. Mol. Pharmacol. 2013, 84(2):236-243.
38. Seo T., Urasaki Y., Ueda T. Establishment of an arsenic trioxide-resistant human leukemia cell line that shows multidrug resistance. Int. J. Hematol. 2007, 85(1):26-31.
39. Zhu H.H., Qin Y.Z., Huang X.J. Resistance to arsenic therapy in acute promyelocytic leukemia. N. Engl. J. Med. 2014, 370(19):1864-1866.
40. Kalaycio M. Clinical experience with bendamustine: a new treatment for patients with chronic lymphocytic leukemia. Clin. Leuk. 2008, 2(4):223-229.
41. Bardal S.K., Waechter J.E., Martin D.S. Applied pharmacology. 3251 Riverport Lane St. Louis, Missouri 63043: Elsevier/Saunders 2010.
42. Panasci L., et al. Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair. Clin. Cancer Res. 2001, 7(3):454-461.
43. Andersson B.S., et al. Mechanisms of cyclophosphamide resistance in a human myeloid leukemia cell line. Acta Oncol. 1995, 34(2):247-251.
44. Gamcsik M.P., et al. Mechanisms of resistance to the toxicity of cyclophosphamide. Curr. Pharm. Des. 1999, 5(8):587-605.
45. Abdullah L.N., Chow E.K.-H. Mechanisms of chemoresistance in cancer stem cells. Clin. Transl. Med. 2013, 2:3-3.
46. Shawi M., et al. Telomerase contributes to fludarabine resistance in primary human leukemic lymphocytes. PLoS ONE 2013, 8(7).
47. Baig N.A., et al. Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement. Leuk. Lymphoma 2012, 53(11):2218-2227.
48. Zent C.S., et al. Direct and complement dependent cytotoxicity in CLL cells from patients with high risk early stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk. Res. 2008, 32(12):1849-1856.
49. Marquez M.E., et al. Bone marrow stromal mesenchymal cells induce down regulation of CD20 expression on B-CLL: implications for rituximab resistance in CLL. Br. J. Haematol. 2015, 169(2):211-218.
50. Ichim C.V. Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors. Stem Cells Transl. Med. 2014, 3(4):405-415.
51. Sison E.A., et al. Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition. Oncotarget 2014, 5(19):8947-8958.
52. Dean M. ABC transporters, drug resistance, and cancer stem cells. J. Mammary Gland Biol. Neoplasia 2009, 14(1):3-9.
53. Persidis A. Cancer multidrug resistance. Nat. Biotechnol. 1999, 17(1):94-95.
54. Kimura Y., et al. Mechanism of multidrug recognition by MDR1/ABCB1. Cancer Sci. 2007, 98(9):1303-1310.
55. Tsuruo T., et al. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci. 2003, 94(1):15-21.
56. Fletcher J.I., et al. ABC transporters in cancer: more than just drug efflux pumps. Nat. Rev. Cancer 2010, 10(2):147-156.
57. Katayama K., Noguchi K., Sugimoto Y. Regulations of P-glycoprotein/ABCB1/MDR1 in human cancer cells. New J. Sci. 2014, 2014:10.
58. Correia A.L., Bissell M.J. The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist. Updat. 2012, 15(1-2):39-49.
59. Scotto K.W. Transcriptional regulation of ABC drug transporters. Oncogene 2003, 22(47):7496-7511.
60. Benabbou N., et al. A subset of bone marrow stromal cells regulate ATP-binding cassette gene expression via insulin-like growth factor-I in a leukemia cell line. Int. J. Oncol. 2014, 45(4):1372-1380.
61. Chen K.G., Sikic B.I. Molecular pathways: regulation and therapeutic implications of multidrug resistance. Clin. Cancer Res. 2012, 18(7):1863-1869.
62. Iwamoto S., et al. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J. Clin. Invest. 2007, 117(4):1049-1057.
63. Patel N., et al. A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug l-asparaginase. J. Clin. Invest. 2009, 119(7):1964-1973.
64. Mudry R.E., et al. Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy. Blood 2000, 96(5):1926-1932.
65. Lynch J.T., et al. The role of glucocorticoid receptor phosphorylation in Mcl-1 and NOXA gene expression. Mol Cancer. 2010: England 2010, 38.
66. Ito C., et al. Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. J. Clin. Oncol. 1996, 14(8):2370-2376.
67. Bachmann P.S., et al. Divergent mechanisms of glucocorticoid resistance in experimental models of pediatric acute lymphoblastic leukemia. Cancer Res. 2007, 67(9):4482-4490.
68. Peinado H., et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 2012, 18(6):883-891.
69. Christopher M.J., et al. Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokine-induced mobilization. Blood 2009, 114(7):1331-1339.
70. Sugiyama T., et al. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006, 25(6):977-988.
71. Colmone A., et al. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science 2008, 322(5909):1861-1865.
72. Wang L., Cheng T., Zheng G. The impact of tumor microenvironments on stem cells. Translational Cancer Research; Vol 2, No 5 (October 2013): Translational Cancer Research (Stem Cells in Cancer) 2013.
73. Espinoza-Hernández L., et al. In vitro characterization of the hematopoietic system in pediatric patients with acute lymphoblastic leukemia. Leuk. Res. 2001, 25(4):295-303.
74. Cheung W.C., Van Ness B. Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells. Leukemia 2002, 16(6):1182-1188.
75. Duan Z., et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin. Cancer Res. 2006, 12(17):5055-5063.
76. Lin B., et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2002, 62(17):5019-5026.
77. Nelson E., Walker S., Frank D. Jak/STAT signaling in the pathogenesis and treatment of multiple myeloma. Advances in Biology and Therapy of Multiple 2013, 117-138. Springer, New York. N.C.M. Myeloma, K.C. Anderson (Eds.).
78. Bataille R., et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995, 86(2):685-691.
79. Wilson T.R., et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012, 487(7408):505-509.
80. Crespo L., Zhang X., Tao J. Targeting the tumor microenvironment for enhancing chemotherapy in hematologic malignancies. Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures 2011, 215-233. Springer, Netherlands. B.R. Minev (Ed.).
81. Urashima M., et al. Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells. Blood 1996, 87(5):1928-1938.
82. Corazza F., et al. Bone marrow stroma damage induced by chemotherapy for acute lymphoblastic leukemia in children. Pediatr. Res. 2004, 55(1):152-158.
83. Bierie B., Moses H.L. Tumour microenvironment: TGF[beta]: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 2006, 6(7):506-520.
84. Tabe Y., et al. TGF-beta-neutralizing antibody 1D11 enhances cytarabine-induced apoptosis in AML cells in the bone marrow microenvironment. PLoS ONE 2013, 8(6).
85. Menzel T., et al. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. Blood 1996, 87(3):1056-1063.
86. Herman S.E.M., et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011, 117(23):6287-6296.
87. Richardson P.G., et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002, 100(9):3063-3067.
88. Ribatti D., Nico B., Vacca A. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene 2006, 25(31):4257-4266.
89. Ding W., et al. Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. Blood 2010, 116(16):2984-2993.
90. Drakakaki G., Dandekar A. Protein secretion: how many secretory routes does a plant cell have?. Plant Sci. 2013, 203-204:74-78.
91. Berleman J., Auer M. The role of bacterial outer membrane vesicles for intra- and interspecies delivery. Environ. Microbiol. 2013, 15(2):347-354.
92. Simons M., Raposo G. Exosomes - vesicular carriers for intercellular communication. Curr. Opin. Cell Biol. 2009, 21(4):575-581.
93. Ratajczak J., et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia 2006, 20(5):847-856.
94. Boyiadzis M., Whiteside T.L. Information transfer by exosomes: a new frontier in hematologic malignancies. Blood Rev. 2015, 10.1016/j.blre.2015.01.004.
95. Peinado H., Lavotshkin S., Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin. Cancer Biol. 2011, 21(2):139-146.
96. Szczepanski M.J., et al. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-β1. Haematologica 2011, 96(9):1302-1309.
97. Huan J., et al. RNA trafficking by acute myelogenous leukemia exosomes. Cancer Res. 2013, 73(2):918-929.
98. Ghosh A.K., et al. Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood 2010, 115(9):1755-1764.
99. Corrado C., et al. Exosome-mediated crosstalk between chronic myelogenous leukemia cells and human bone marrow stromal cells triggers an Interleukin 8-dependent survival of leukemia cells. Cancer Lett. 2014, 348(1):71-76.
100. Bruno S., et al. Microvesicles derived from human bone marrow mesenchymal stem cells inhibit tumor growth. Stem Cells Dev. 2013, 22(5):758-771.
101. Roccaro A.M., et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J. Clin. Invest. 2013, 123(4):1542-1555.
102. Liu J., et al. Abstract 1506: Bone marrow microenvironment mediated redox adaptation confers drug resistance in acute lymphoblastic leukemia. Cancer Res. 2012, 72(8 Supplement):1506-1506.
103. Burger J.A., Gribben J.G. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin. Cancer Biol. 2014, 24:71-81.
104. Lutzny G., et al. Protein kinase C-β-dependent activation of NF-κB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo. Cancer Cell 2013, 23(1):77-92.
105. Kurtova A.V., et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 2009, 114(20):4441-4450.
106. Shishido S., Bönig H., Kim Y.-M. Role of integrin alpha4 in drug resistance of leukemia. Front. Oncol. 2014, 4.
107. Liu C.-C., et al. The membrane-proximal KXGFFKR motif of α-integrin mediates chemoresistance. Mol. Cell. Biol. 2013, 33(21):4334-4345.
108. Spaeth E., et al. Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther. 2008: England 2008, 730-738.
109. Allavena P., et al. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol. Rev. 2008, 222:155-161.
110. Keibel A., Singh V., Sharma M.C. Inflammation, microenvironment, and the immune system in cancer progression. Curr. Pharm. Des. 2009, 15(17):1949-1955.
111. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357(9255):539-545.
112. Balkwill F., Charles K.A., Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005, 7(3):211-217.
113. Perkins N.D. The diverse and complex roles of NF-kappaB subunits in cancer. Nat. Rev. Cancer 2012, 12(2):121-132.
114. Stoffel A., et al. Activation of NF-kappaB and inhibition of p53-mediated apoptosis by API2/mucosa-associated lymphoid tissue 1 fusions promote oncogenesis. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(24):9079-9084.
115. Karin M., et al. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2002, 2(4):301-310.
116. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 2004, 4(1):11-22.
117. Balkwill F. Tumor necrosis factor or tumor promoting factor?. Cytokine Growth Factor Rev. 2002, 13(2):135-141.
118. Micheau O., Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003, 114(2):181-190.
119. Hanahan D., Weinberg Robert A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
120. Ferreri A.J., Ernberg I., Copie-Bergman C. Infectious agents and lymphoma development: molecular and clinical aspects. J. Intern. Med. 2009, 265(4):421-438.
121. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140(6):883-899.
122. Warzocha K., et al. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients. J. Clin. Oncol. 1997, 15(2):499-508.
123. Wiemels J. Perspectives on the causes of childhood leukemia. Chem. Biol. Interact. 2012, 196(3):59-67.
124. Greaves M. Infection, immune responses and the aetiology of childhood leukaemia. Nat. Rev. Cancer 2006, 6(3):193-203.
125. Strachan D.P. Hay fever, hygiene, and household size. BMJ 1989, 299(6710):1259-1260.
126. Chiorazzi N., Rai K.R., Ferrarini M. Chronic lymphocytic leukemia. N. Engl. J. Med. 2005, 352(8):804-815.
127. Enzler T., et al. Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression. Blood 2009, 114(20):4469-4476.
128. Granziero L., et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001, 97(9):2777-2783.
129. Pedersen I.M., et al. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood 2002, 100(5):1795-1801.
130. Tricot G.J. New insights into role of microenvironment in multiple myeloma. Int. J. Hematol. 2002, 76(Suppl. 1):334-336.
131. Kastritis E., Palumbo A., Dimopoulos M.A. Treatment of relapsed/refractory multiple myeloma. Semin. Hematol. 2009, 46(2):143-157.
132. Gambacorti-Passerini C., et al. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J. Natl. Cancer Inst. 2000, 92(20):1641-1650.
133. Harvey R.D., Morgan E.T. Cancer, inflammation, and therapy: effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents. Clin. Pharmacol. Ther. 2014, 96(4):449-457.
134. Leung T., et al. Cytochrome P450 2E1 (CYP2E1) regulates the response to oxidative stress and migration of breast cancer cells. Breast Cancer Res. 2013, 15(6):R107.
135. Nagai F., et al. Cytochrome P450 (CYP) expression in human myeloblastic and lymphoid cell lines. Biol. Pharm. Bull. 2002, 25(3):383-385.
136. Sulicka J., et al. Elevated markers of inflammation and endothelial activation and increased counts of intermediate monocytes in adult survivors of childhood acute lymphoblastic leukemia. Immunobiology 2013, 218(5):810-816.
137. Schiller J.T., Muller M. Next generation prophylactic human papillomavirus vaccines. Lancet Oncol. 2015, 16(5):e217-e225.
138. Scott A.M., Allison J.P., Wolchok J.D. Monoclonal antibodies in cancer therapy. Cancer Immun. 2012, 12.
139. Swann J.B., Smyth M.J. Immune surveillance of tumors. J. Clin. Invest. 2007, 117(5):1137-1146.
140. Zeng D., et al. Unique patterns of surface receptors, cytokine secretion, and immune functions distinguish T cells in the bone marrow from those in the periphery: impact on allogeneic bone marrow transplantation. Blood 2002, 99(4):1449-1457.
141. del Campo A.B., et al. Targeting HLA class I expression to increase tumor immunogenicity. Tissue Antigens 2012, 79(3):147-154.
142. Stolzel F., et al. Clonal evolution including partial loss of human leukocyte antigen genes favoring extramedullary acute myeloid leukemia relapse after matched related allogeneic hematopoietic stem cell transplantation. Transplantation 2012, 93(7):744-749.
143. Teague R.M., Kline J. Immune evasion in acute myeloid leukemia: current concepts and future directions. J. Immunother. Cancer 2013, 1(13).
144. Zhu C., et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 2005, 6(12):1245-1252.
145. Wu W., et al. Blockade of Tim-3 signaling restores the virus-specific CD8(+) T-cell response in patients with chronic hepatitis B. Eur. J. Immunol. 2012, 42(5):1180-1191.
146. Golden-Mason L., et al. Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J. Virol. 2009, 83(18):9122-9130.
147. Sakuishi K., et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 2010, 207(10):2187-2194.
148. Wu G. Functional amino acids in growth, reproduction, and health. Adv. Nutr. 2010, 1(1):31-37.
149. Capece L., et al. The first step of the dioxygenation reaction carried out by tryptophan dioxygenase and indoleamine 2,3-dioxygenase as revealed by quantum mechanical/molecular mechanical studies. J. Biol. Inorg. Chem. 2010, 15(6):811-823.
150. Frumento G., et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 2002, 196(4):459-468.
151. Munn D.H., et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002, 297(5588):1867-1870.
152. Fallarino F., et al. Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol. 2003, 4(12):1206-1212.
153. Fallarino F., et al. CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice. J. Exp. Med. 2004, 200(8):1051-1062.
154. Mellor A.L., Munn D.H. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?. Immunol. Today 1999, 20(10):469-473.
155. Fallarino F., et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 2006, 176(11):6752-6761.
156. + T regulatory cells. Blood 2007, 109(7):2871-2877.
157. Moshaver B., et al. Chemotherapeutic treatment of bone marrow stromal cells strongly affects their protective effect on acute myeloid leukemia cell survival. Leuk. Lymphoma 2008, 49(1):134-148.
158. Soderquist R., et al. Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivo. Leukemia 2013, 27(11):2262-2264.
159. Gabrilove J.L. Angiogenic growth factors: autocrine and paracrine regulation of survival in hematologic malignancies. Oncologist 2001, 6(Suppl. 5):4-7.
160. Medinger M., Passweg J. Role of tumour angiogenesis in haematological malignancies. Swiss Med. Wkly. 2014, 144.
161. Gupta D., et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001, 15(12):1950-1961.
162. Hideshima T., et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001, 61(7):3071-3076.
163. Waldmann T.A. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J. Clin. Immunol. 2007, 27(1):1-18.
164. Mahnke K., et al. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int. J. Cancer 2007, 120(12):2723-2733.
165. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331(6024):1565-1570.
166. Hodi F.S., et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(8):4712-4717.
167. Vasaturo A., et al. Clinical implications of co-inhibitory molecule expression in the tumor microenvironment for DC vaccination: a game of stop and go. Front. Immunol. 2013, 4:417.
168. Keir M.E., et al. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008, 26:677-704.
169. Zitvogel L., Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 2012, 1(8):1223-1225.
170. Wilcox R.A., et al. The B7 homologues and their receptors in hematologic malignancies. Eur. J. Haematol. 2012, 88(6):465-475.
171. Taube J.M., et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 2014, 20(19):5064-5074.
172. Brahmer J.R., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 2010, 28(19):3167-3175.
173. Rosenblatt J., et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J. Immunother. 2011, 34(5):409-418.
174. Patnaik A., et al. Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. J Clin Oncol 2012, (Chicago, Illinois. p. suppl; abstr 2512).
175. Chen D.S., Irving B.A., Hodi F.S. Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1. Clin. Cancer Res. 2012, 18(24):6580-6587.
176. Ascierto P.A., et al. Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin. Cancer Res. 2013, 19(5):1009-1020.
177. Fourcade J., et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J. Exp. Med. 2010, 207(10):2175-2186.
178. Ngiow S.F., et al. Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors. Cancer Res. 2011, 71(10):3540-3551.
179. Gao X., et al. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS ONE 2012, 7(2).
180. Wingender G., et al. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur. J. Immunol. 2006, 36(1):12-20.
181. Munn D.H. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr. Opin. Immunol. 2006, 18(2):220-225.
182. Jiang T., et al. Research progress of indoleamine 2,3-dioxygenase inhibitors. Future Med. Chem. 2015, 7(2):185-201.
183. Kwidzinski E., et al. Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. FASEB J. 2005, 19(10):1347-1349.
184. Lodhia K.A., et al. Prioritizing therapeutic targets using patient-derived xenograft models. Biochim. Biophys. Acta Rev. Cancer 2015, 1855(2):223-234.
185. Mendez-Ferrer S., Frenette P.S. Hematopoietic stem cell trafficking: regulated adhesion and attraction to bone marrow microenvironment. Ann. N. Y. Acad. Sci. 2007, 1116:392-413.
186. Motabi I.H., DiPersio J.F. Advances in stem cell mobilization. Blood Rev. 2012, 26(6):267-278.
187. Calvi L.M. Osteoblastic activation in the hematopoietic stem cell niche. Ann. N. Y. Acad. Sci. 2006, 1068:477-488.
188. Rettig M.P., Ansstas G., DiPersio J.F. Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4. Leukemia 2012, 26(1):34-53.
189. Reikvam H., et al. Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release. Expert Opin. Investig. Drugs 2010, 19(2):169-183.
190. Ono M., et al. Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells. Sci. Signal. 2014, 7(332):ra63.